We advised the underwriters on the notes offering

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered debt offering by Merck & Co., Inc. of $8 billion aggregate principal amount of notes. The notes were offered in eight tranches, including floating-rate notes maturing in 2029 and fixed-rate notes maturing in 2029, 2031, 2032, 2035, 2046, 2055 and 2065.

Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its operations are principally managed on a product basis and include two operating segments, pharmaceutical and animal health.

The Davis Polk capital markets team included partner Stephen A. Byeff and associates Raphaelle Desaleux and Sierra M. Acosta. The tax team included counsel Tracy L. Matlock and associate Valentin Van de Walle. All members of the Davis Polk team are based in the New York office.

Copy link to share post